Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy

SIMPLE SUMMARY: Regorafenib and TAS-102 showed a survival benefit against placebo, and both drugs are approved for the treatment of metastatic colorectal cancer (mCRC) beyond second-line. The highly differential toxicity profile of both substances has led to a potentially biased perception of drug t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers (Basel)
Hauptverfasser: Huemer, Florian, Piringer, Gudrun, Schlintl, Verena, Hackl, Hubert, Rinnerthaler, Gabriel, Thaler, Josef, Greil, Richard, Weiss, Lukas
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7599669/
https://ncbi.nlm.nih.gov/pubmed/33007814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12102812
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge